{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T10:14:31Z","timestamp":1788171271713,"version":"build-2803163510"},"reference-count":20,"publisher":"Jaypee Brothers Medical Publishing","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.59556\/japi.74.1583","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T10:58:07Z","timestamp":1784199487000},"page":"24-27","source":"Crossref","is-referenced-by-count":0,"title":["Profile of Philadelphia Chromosome Negative (Ph-) Myeloproliferative Neoplasm with Special Emphasis on Vascular Thrombotic Events and the Response to Cytoreductive Therapy in Polycythemia Vera and Essential Thrombocythemia Patients: A Single Center Study from Kerala"],"prefix":"10.59556","volume":"74","author":[{"given":"Raghuveer Santhakumara","family":"Prabhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahmathullah Sulaimankutty","family":"Nameera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayyid Muhammed Lukhmanulhakkim","family":"Thangal K","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka R","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2914","reference":[{"key":"key20260831091930_B1","doi-asserted-by":"crossref","unstructured":"Li W. The 5th edition of the World Health Organization classification of hematolymphoid tumors. In: Li W, editor. Leukemia [Internet]. Brisbane (AU): Exon Publications; 2022 Oct 16. Chapter 1. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK586208\/ DOI: 10.36255\/exon-publications-leukemia-who-5th-edition-hematolymphoid-tumors","DOI":"10.36255\/exon-publications-leukemia-who-5th-edition-hematolymphoid-tumors"},{"issue":"(11):","key":"key20260831091930_B2","doi-asserted-by":"crossref","first-page":"1200\u2013","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.","volume":"140","author":"Arber","year":"2022;","journal-title":"Blood"},{"key":"key20260831091930_B3","doi-asserted-by":"crossref","first-page":"167.","DOI":"10.1186\/s12885-016-2208-2","article-title":"Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey.","volume":"16:","author":"Mesa","year":"2016;","journal-title":"BMC Cancer"},{"issue":"(5):","key":"key20260831091930_B4","doi-asserted-by":"crossref","first-page":"1057\u2013","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.","volume":"32","author":"Barbui","year":"2018;","journal-title":"Leukemia"},{"issue":"(1):","key":"key20260831091930_B5","doi-asserted-by":"crossref","first-page":"21\u2013","DOI":"10.1182\/bloodadvances.2016000216","article-title":"Targeted deep sequencing in polycythemia vera and essential thrombocythemia.","volume":"1","author":"Tefferi","year":"2016;","journal-title":"Blood Adv"},{"key":"key20260831091930_B6","doi-asserted-by":"crossref","first-page":"58.","DOI":"10.1186\/1472-6807-9-58","article-title":"Structural effects of clinically observed mutations in JAK2 exons 13-15: comparison with V617F and exon 12 mutations.","volume":"9:","author":"Lee","year":"2009;","journal-title":"BMC Struct Biol"},{"key":"key20260831091930_B7","doi-asserted-by":"crossref","first-page":"184.","DOI":"10.1186\/s12885-019-5387-9","article-title":"A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms.","volume":"19:","author":"Rungjirajittranon","year":"2019;","journal-title":"BMC Cancer"},{"issue":"(5):","key":"key20260831091930_B8","doi-asserted-by":"crossref","first-page":"360\u2013","DOI":"10.1016\/j.clml.2023.01.012","article-title":"Distinctive attributes of Indian patients with classical BCR::ABL1-negative myeloproliferative neoplasms: unified clinical and laboratory data.","volume":"23","author":"Singh","year":"2023;","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"(11):","key":"key20260831091930_B9","doi-asserted-by":"crossref","first-page":"4214\u2013","DOI":"10.1182\/blood-2005-08-3526","article-title":"Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia.","volume":"107","author":"Schafer","year":"2006;","journal-title":"Blood"},{"issue":"(10):","key":"key20260831091930_B10","doi-asserted-by":"crossref","first-page":"1544\u2013","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.","volume":"123","author":"Rumi","year":"2014;","journal-title":"Blood"},{"issue":"(10):","key":"key20260831091930_B11","doi-asserted-by":"crossref","first-page":"1552\u2013","DOI":"10.1182\/blood-2013-11-538983","article-title":"Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia.","volume":"123","author":"Rotunno","year":"2014;","journal-title":"Blood"},{"issue":"(5):","key":"key20260831091930_B12","doi-asserted-by":"crossref","first-page":"813\u2013","DOI":"10.1111\/bjh.13539","article-title":"Impaired leucocyte activation is underlining the lower thrombotic risk of essential thrombocythaemia patients with CALR mutations as compared with those with the JAK2 mutation.","volume":"172","author":"Torregrosa","year":"2016;","journal-title":"Br J Haematol"},{"key":"key20260831091930_B13","doi-asserted-by":"crossref","first-page":"11.","DOI":"10.1038\/s41408-023-00972-x","article-title":"One thousand patients with essential thrombocythemia: the Mayo Clinic experience.","volume":"14:","author":"Gangat","year":"2024;","journal-title":"Blood Cancer J"},{"issue":"(17):","key":"key20260831091930_B14","doi-asserted-by":"crossref","first-page":"1889\u2013","DOI":"10.1182\/blood-2017-05-785790","article-title":"Cross, Ruben Mesa, Mary Frances McMullin; Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.","volume":"130","author":"Harrison","year":"2017;","journal-title":"Blood"},{"key":"key20260831091930_B15","doi-asserted-by":"crossref","first-page":"8073\u2013","DOI":"10.1002\/cam4.5602","article-title":"Prognostic value of modified criteria for hydroxyurea resistance or intolerance in patients with high-risk essential thrombocythemia.","volume":"12:","author":"Park","year":"2023;","journal-title":"Cancer Med"},{"issue":"(11):","key":"key20260831091930_B16","first-page":"1158.","article-title":"Genetic landscape of myeloproliferative neoplasms with an emphasis on molecular diagnostic laboratory testing.","volume":"11","author":"Easwar","year":"2021;","journal-title":"Life (Basel)"},{"issue":"(1):","key":"key20260831091930_B17","first-page":"27\u2013","article-title":"Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with myeloproliferative disorders.","volume":"10","author":"Tevet","year":"2015;","journal-title":"Maedica (Bucur)"},{"issue":"(6):","key":"key20260831091930_B18","doi-asserted-by":"crossref","first-page":"2096\u2013","DOI":"10.1002\/cam4.2886","article-title":"Thrombosis among 1537 patients with JAK2V617F -mutated myeloproliferative neoplasms: risk factors and development of a predictive model.","volume":"9","author":"Zhang","year":"2020;","journal-title":"Cancer Med"},{"issue":"(1):","key":"key20260831091930_B19","doi-asserted-by":"crossref","first-page":"17819.","DOI":"10.1038\/s41598-021-97464-4","article-title":"Incidence, characteristics and risk factors of thromboembolic events in East Asian patients with BCR-ABL1 negative myeloproliferative neoplasms.","volume":"11","author":"Kim","year":"2021;","journal-title":"Sci Rep"},{"issue":"(5):","key":"key20260831091930_B20","first-page":"734\u2013","article-title":"Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea.","volume":"7","author":"Wang","year":"2023;","journal-title":"Blood Adv"}],"container-title":["Journal of The Association of Physicians of India"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T09:19:41Z","timestamp":1788167981000},"score":1,"resource":{"primary":{"URL":"https:\/\/japi.org\/article\/japi-74-7-24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.59556\/japi.74.1583"],"URL":"https:\/\/doi.org\/10.59556\/japi.74.1583","relation":{},"ISSN":["0004-5772"],"issn-type":[{"value":"0004-5772","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}